Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab effects on actinic keratoses in advanced cutaneous squamous cell carcinoma
2021-006372-17Phase 4Completed
- Sponsor
- Mühlenkreiskliniken
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC) and actinic keratosis (AK), sponsored by Mühlenkreiskliniken. Primary endpoint: Clinical assessment of the severity of actinic keratoses during PD-1 inhibitor therapy. Started Dec 2021; status: completed.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)actinic keratosis (AK)
Beyond the preview
Go deeper on 2021-006372-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006372-17.